Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MANA Pharma
Waltham, Massachusetts, United Statesmanatx.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
MANA Therapeutics was a clinical-stage biotechnology company focused on developing off-the-shelf, allogeneic T-cell therapies for the treatment of cancer. The company's proprietary EDDIE (Educated Antigen-Specific T Cell) platform was designed to identify and target multiple tumor-associated antigens (TAAs) simultaneously, aiming to overcome tumor heterogeneity and prevent immune escape. Its lead program, MANA-312, was being evaluated in patients with relapsed or refractory acute myeloid leukemia (AML) and other myeloid malignancies. Despite its innovative approach and early clinical progress, the company announced a wind-down of its operations in late 2022 due to funding challenges.
- Therapeutic areas
- HematologyOncology
- Modalities
- Cell therapyT cell therapy
- Industry
- Biotech
Beyond the preview
Go deeper on MANA Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MANA Pharma.